Monte Rosa Therapeutics, Inc. Common Stock (GLUE)

Price$19.67

Value ScoreD

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)29.85%

Price vs S&P 500 (4W)-0.13%

VGM Score39.10

Market Capitalization$1.67B

All Metrics

P/CF (Annual)32.71x

Book Value / Share (Quarterly)$6.19

P/TBV (Annual)0.55x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.23

Price vs S&P 500 (YTD)14.77%

Net Profit Margin (TTM)-302.69%

EPS (TTM)$-1.46

10-Day Avg Trading Volume0.85M

EPS Excl Extra (TTM)$-1.46

EPS (Annual)$-0.47

ROI (Annual)-16.57%

Cash / Share (Quarterly)$7.90

P/E Basic Excl Extra (TTM)65.59x

Revenue Growth QoQ (YoY)-95.04%

ROA (Last FY)-8.61%

Revenue Growth TTM (YoY)-73.07%

EBITD / Share (TTM)$-1.60

ROE (5Y Avg)-37.19%

Operating Margin (TTM)-345.21%

Cash Flow / Share (Annual)$-0.42

P/B Ratio3.19x

P/B Ratio (Quarterly)2.52x

Net Income / Employee (Annual)$-257,500

EV / Revenue (TTM)35.04x

Net Interest Coverage (TTM)-615.33x

ROA (TTM)-25.94%

EV / EBITDA (TTM)89.38x

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)6.12x

Quick Ratio (Quarterly)9.44x

3-Month Avg Trading Volume1.02M

52-Week Price Return365.96%

EV / Free Cash Flow (Annual)30.67x

P/E Incl Extra (TTM)65.59x

Revenue / Employee (TTM)$286,400

Tangible BV / Share (Quarterly)$3.69

P/S Ratio (Annual)13.46x

Asset Turnover (Annual)0.28x

52-Week High$25.77

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)6.75%

26-Week Price Return45.78%

Quick Ratio (Annual)6.05x

13-Week Price Return6.54%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.54x

Enterprise Value$1.51B

Asset Turnover (TTM)0.09x

Revenue / Employee (Annual)$824,500

Pretax Margin (Annual)-32.12%

Cash / Share (Annual)$5.75

3-Month Return Std Dev48.72%

Net Income / Employee (TTM)$-866,800

ROE (Last FY)-16.57%

Net Interest Coverage (Annual)-125.82x

EPS Basic Excl Extra (Annual)$-0.47

EV / Free Cash Flow (TTM)8.04x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.46

ROI (TTM)-40.99%

P/S Ratio (TTM)38.77x

Revenue / Share (Annual)$1.49

Tangible BV / Share (Annual)$5.50

Price vs S&P 500 (52W)337.75%

P/E Ratio (TTM)65.59x

Year-to-Date Return25.70%

5-Day Price Return4.78%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)-24.32%

Net Profit Margin (Annual)-31.23%

Month-to-Date Return2.92%

Cash Flow / Share (TTM)$-2.58

EBITD / Share (Annual)$-0.55

Operating Margin (Annual)-43.83%

P/CF (TTM)9.21x

ROI (5Y Avg)-37.19%

P/E Excl Extra (TTM)65.59x

EPS Basic Excl Extra (TTM)$-1.46

P/TBV (Quarterly)0.81x

P/B Ratio (Annual)4.38x

Pretax Margin (TTM)-307.04%

Book Value / Share (Annual)$3.56

Price vs S&P 500 (13W)-3.21%

Beta1.59x

P/FCF (Annual)43.81x

Revenue / Share (TTM)$0.43

ROE (TTM)-40.99%

52-Week Low$3.90

vGradeD

gGradeF

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.45est. -0.39

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.27

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	B	$19.67
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), a novel class of small molecules designed to selectively degrade disease-relevant proteins by harnessing the body's natural protein destruction mechanisms. Leveraging its proprietary QuEEN platform and AI-driven discovery, the company has assembled a library of over 50,000 MGD candidates. Its lead program, MRT-2359, targets GSPT1 in MYC-driven tumors.